Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : ¿¬±¸¼Ò ´º½º
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [ÀǾàǰÁ¤Ã¥¸®Æ÷Æ®]ÀÀ´äÀÚ 94.3% µµÀÔ Âù¼º¡¦Àü¹®Àû »ó´ã Àý½Ç
³»   ¿ë
Âü¿© ¿¬±¸¿ø ÀÓÀ翵 ½ÇÀå/±èÁøÀ̠åÀÓ¿¬±¸¿ø/Á¤µ¿¿í ºÎ¼±ÀÓ¿¬±¸¿ø
ÆíÁý ÀÌÁÖÇÏ ÁÖÀÓ¿¬±¸¿ø


°øÀû ¸¶½ºÅ© ÆÇ¸Å·Î Å« °ü½ÉÀ» ¹ÞÀº ¾à±¹ÀÇ °æ¿ì Àü±¹ Æò±Õ Á¢±Ù¼ºÀÌ 5.04kmÀ̳ª ¼­¿ï Æò±Õ 0.94km, °­¿øµµ 9.24km·Î Áö¿ª °£ÀÇ Á¢±Ù¼º °ÝÂ÷°¡ ¸Å¿ì Å©°í, '¾à±¹ ¼­ºñ½º ±Ç¿ª ¿Ü Ãë¾àÀα¸ ºñÀ²'¿¡ µû¸£¸é °¡Àå °¡±î¿î ¾à±¹±îÁö µµº¸·Î 10ºÐ ÀÌ»ó(750m ±âÁØ) ¼Ò¿äµÇ´Â Áö¿ª¿¡ °ÅÁÖÇϴ Ãë¾àÀα¸(¿µÀ¯¾Æ Àα¸ ¹× °í·É Àα¸)´Â 35.4%¿¡ ´ÞÇϴ °ÍÀ¸·Î ³ªÅ¸³µ´Ù.

ÀÌ º¸°í¼­´Â Æ÷½ºÆ® Äڷγª ½Ã´ë¿¡ ±¹¹Î »ýȰ¿©°ÇÀ» Áø´ÜÇØ ¾ÈÀüÇÏ°í Æí¸®ÇÑ »ýȰ¿©°ÇÀ» Á¶¼ºÇϴµ¥ È°¿ëÇϸç, Á¤Ã¥¿¡ ¹Ý¿µÇÒ ¼ö ÀÖµµ·Ï °ü·Ã Á¦µµ ±â¹ÝÀ» ¸¶·ÃÇÒ °èȹÀ̶ó°í ¹àÇû´Ù. Á౹Àº Áö¿ª»çȸÀÇ »ýȰ°£Á¢ÀÚº»(Social Overhead Capital, SOC)À¸·Î¼­ ³· ½Ã°£ »Ó ¾Æ´Ï¶ó, ½É¾ß½Ã°£¿¡µµ ÀûÁ¤ÇÑ ¿î¿µÀÌ ¿ä±¸µÇ°í ÀÖ´Ù.

½É¾ß½Ã°£´ë ÀǾàǰ ¹× º¹¾àÁöµµ°¡ ÇÊ¿äÇѠȯÀÚ¿¡°Ô ¾ÈÀü»óºñÀǾàǰ¸¸À¸·Î´Â ÇѰ谡 ÀÖ´Ù. ±¤ÁÖ±¤¿ª½Ã¿¡¼­ ÀÌ·ç¾îÁø °ø°ø½É¾ß¾à±¹ÀÇ Çʿ伺À» ¹¯´Â ¼³¹® °á°ú¿¡ µû¸£¸é, 281¸íÀÇ ÀÀ´äÀÚÀÇ 90% ÀÌ»óÀÌ ½É¾ß ½Ã°£¿¡ ¾à±¹À» ÀÌ¿ëÇÏÁö ¸øÇØ ºÒÆíÇß´ø °æÇèÀÌ ÀÖ¾ú°í, 94.3%ÀÇ ÀÀ´äÀÚ°¡ ½É¾ß¾à±¹ µµÀÔ¿¡ Âù¼ºÇß´Ù. 

°æÁõ¿¡µµ ÀÀ±Þ½ÇÀ» ¹æ¹®Çϴ °ÍÀÌ ºÒÆíÇߴٴ ´äº¯°ú ÆíÀÇÁ¡¿¡¼­ ¾àÀ» ±¸¸ÅÇßÁö¸¸, Àü¹®ÀûÀΠ»ó´ãÀÌ ¾ø¾î¼­ ºÒ¾ÈÇߴٴ ´äº¯ÀÌ ÀÖ¾ú´Ù. 

ÀÌ¿¡, ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò´Â ±¹³»¿Ü °ø°ø½É¾ß¾à±¹ »ç·Ê¸¦ Á¶»çÇϰí ÀÌ¿ëÀÚ ¸¸Á·µµ¸¦ Á¶»ç¡¤ºÐ¼®ÇÔÀ¸·Î½á È¿À²ÀûÀΠ½É¾ß¾à±¹ ¿î¿µ ¹× Áö¿øÀ» À§ÇÑ ÇÕ¸®ÀûÀΠÁ¤Ã¥ °³¼± ¹æ¾ÈÀ» Á¦½ÃÇϱâ À§ÇØ 2020³â 7¿ùºÎÅÍ 11¿ù±îÁö '°ø°ø½É¾ß¾à±¹ »ç¾÷Æò°¡'¿¬±¸¸¦ ÁøÇàÇß´Ù. ¿¬±¸³»¿ëÀº ´ÙÀ½°ú °°¾Ò´Ù.

ù°, ±¹³»¿Ü Ãë¾à½Ã°£´ë ¾à·á ¼­ºñ½º À̿렰ü·Ã »ç·Ê¸¦ Á¶»ç¡¤ºÐ¼®Çß´Ù. ±¹³» ¿î¿µ ÁßÀΠÁöÀÚüº° ½É¾ß¾à±¹ ¿î¿µ »ç·Ê, Áö¿ªº° °ø°ø½É¾ß¾à±¹ÀÇ Á¶·Ê, ¿î¿µ ÇöȲ, Áö¿ø±Ý¾×, È«º¸¿Í °ü·ÃµÈ ³»¿ëÀ» Á¶»çÇØ ±× Æ¯Â¡À» ÆÄ¾ÇÇß´Ù.  ¶ÇÇÑ, ±¹¿Ü ¾ß°£¡¤ÈÞÀÏ µî Ãë¾à½Ã°£´ë ¾à·á ¼­ºñ½º À̿렻ç·Ê¸¦ Á¶»ç¡¤ºÐ¼®ÇØ ½Ã»çÁ¡À» µµÃâÇß´Ù.

µÑ°, °ø°ø½É¾ß¾à±¹ »ç¾÷ ½ÇÀû ÀڷḦ ºÐ¼®ÇØ ¼­ºñ½ºº° ÃѰý ½ÇÀûÀÇ ºóµµ ¹× ÃßÀÌ ºÐ¼®À» Çß´Ù. ¼ºº° ³ªÀÌ µî ÀÌ¿ëÀڠƯ¼ºº° ½ÇÀûÀÇ ºóµµ ¹× ÃßÀÌ ºÐ¼®°ú ½Ã°£´ë, ÀǾàǰ µî ÀÌ¿ë Æ¯¼º¿¡ µû¸¥ ºóµµ ¹× ÃßÀÌ ºÐ¼®À» ¼öÇàÇß´Ù.

¼Â°, °ø°ø½É¾ß¾à±¹ ÀÌ¿ëÀÚ ¸¸Á·µµ Æò°¡¸¦ À§ÇØ ÇöÀ砿 ÁßÀΠÁ¦ÁÖµµ Áö¿ªÀÇ °ø°ø½É¾ß¾à±¹À» ´ë»óÀ¸·Î ¼³¹® Á¶»ç¸¦ ÇØ ½ÇŸ¦ ÆÄ¾ÇÇß´Ù. °ø°ø½É¾ß¾à±¹ÀÇ ÀÎÁöµµ ¹× ÀÎÁö°æ·Î¸¦ ÆÄ¾ÇÇßÀ¸¸ç, À̿렰æÇè ¹× À̿렸¸Á·µµ ¹× ÇâÈÄ ÀÌ¿ë ÀÇÇâÀ» Á¶»çÇß´Ù.

³Ý°, Âü¿© ¾à±¹ ¼±Á¤ ±âÁØ µîÀ» ÅëÇÑ ÅõÀÔ ÀÚ¿øÀÇ ÀûÁ¤¼º, ¿ùÆò±Õ ¾à±¹ ´ç ÀÌ¿ëÀÚ ¼ö¸¦ ÅëÇÑ ÀÚ¿øÀǠȰ¿ë Á¤µµ¸¦ ÆÄ¾Ç, Áö¿ø ±Ý¾×À» ÅëÇÑ ÁöÀÚü Áö¿øÀÇ ÀûÀý¼º°ú ÀÌ¿ëÀÚ ¸¸Á·µµ Á¶»ç, ¾à»ç´ë»ó Á¶»ç¸¦ ÅëÇÑ °ø°ø½É¾ß¾à±¹ »ç¾÷À» Æò°¡Ç졒ʡ³¼±¹æ¾ÈÀ» Á¦½ÃÇß´Ù.

1. ±¹³»¿Ü ÇöȲ ¹× »ç·ÊÁ¶»ç
(1) ±¹³»
±¹³» °ø°ø½É¾ß¾à±¹Àº 8°³ Áö¿ªÀÇ 82°÷ÀÇ °ø°ø½É¾ß¾à±¹ÀÌ ¿î¿µ ÁßÀ̾ú´Ù. 2012³â Á¦ÁÖÆ¯º°ÀÚÄ¡µµ(ÀÌÇÏ, Á¦ÁÖµµ)ÀÇ ½Ã¹ü»ç¾÷À¸·Î Ã³À½ ½ÃÀÛµÆÀ¸¸ç, Á¦ÁÖµµ 7°÷, ´ë±¸±¤¿ª½Ã(ÀÌÇÏ, ´ë±¸½Ã) 12°÷, °æ±âµµ°¡ 16°÷, ´ëÀü±¤¿ª½Ã(ÀÌÇÏ, ´ëÀü½Ã) 2°÷, ÀÎõ±¤¿ª½Ã(ÀÌÇÏ, ÀÎõ½Ã) 6°÷, ±¤ÁÖ±¤¿ª½Ã(ÀÌÇÏ, ±¤ÁÖ½Ã) 2°÷, ¼­¿ïƯº°½Ã(ÀÌÇÏ, ¼­¿ï½Ã) 31°÷ÀÌ´Ù(2020. 11. 30. ±âÁØ).

¿î¿µ½Ã°£ ¹× Áö¿ø±Ý¾×Àº Áö¿ªº°·Î »óÀÌÇßÀ¸¸ç, 20~23½Ã ¿î¿µ°ú ½Ã°£´ç 3¸¸¿ø Áö¿øºñÀÇ ÇüŰ¡ °¡Àå ¸¹¾Ò´Ù. PIT3000À» ÅëÇØ µ¥ÀÌÅ͸¦ ÀÔ·ÂÇϴ °÷Àº Á¦ÁÖµµ, °æ±âµµ, ¼­¿ï½Ã¿´À¸¸ç, µ¥ÀÌÅÍ Ç׸ñ, ³»¿ë, ¹æ¹ý µîÀÌ Áö¿ªº°·Î »óÀÌÇß´Ù.

(2) ±¹¿Ü
1) È£ÁÖ
´Ù¸¥ ÁÖ¿Í ¸¶Âù°¡Áö·Î, ºòÅ丮¾ÆÁÖÀÇ °æ¿ì¿¡µµ È¯ÀÚµéÀº º´¿øÀÇ ±Ù¹« ½Ã°£ ¿ÜÀÇ °æ¹ÌÇÑ ºÎ»ó ¹× Áúº´¿¡ ´ëÇØ À¯ÀÏÇϰԠ¼±ÅÃÇÒ ¼ö Àִ °÷Àº Áö¿ªº´¿øÀÇ ÀÀ±Þ½ÇÀ̾ú´Ù. 


±×·¯³ª, ºòÅ丮¾ÆÁÖ Á¤ºÎ´Â ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇذáÇϰíÀÚ 2016³âºÎÅÍ °ø°ø½É¾ß¾à±¹À» ÃßÁøÇØ 2017³â¿¡ 7°³¸¦ ¿î¿µÇßÀ¸¸ç, 2020³â ÇöÀ砽ɾ߾౹ÀΠ'Supercare ¾à±¹'Àº 6°³ Áö¿ª¿¡¼­ 20°³°¡ ¿î¿µ ÁßÀÌ´Ù. <´ÙÀ½È£¿¡ °è¼Ó>

 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
129 [´ëÇѾà»çÀú³Î]°ø°ø½É¾ß¾à±¹, »ç¾÷ È®´ë À§ÇØ ¿î¿µ¡¤ÆíÀÇ °³¼± ÇÊ¿ä ÀÌÁÖÇÏ 2021-09-23 1110
128 [´ëÇѾà»çÀú³Î]½É¾ß½Ã°£ ¾à±¹ ÀÌ¿ë '¸¸Á·ÇÑ´Ù' 93.5% ÀÌÁÖÇÏ 2021-09-23 985
127 [´ëÇѾà»çÀú³Î]¿µ±¹, OHH ¼­ºñ½º ÀϹݾࡤÀü¹®¾à ³ª´² Á¦°ø ÀÌÁÖÇÏ 2021-09-23 948
126 [´ëÇѾà»çÀú³Î]È£ÁÖ ¹ãÀ» ¹àÈ÷´Â 'Supercare' ¾à±¹ ÀÌÁÖÇÏ 2021-09-23 966
125 [ÀǾàǰÁ¤Ã¥¸®Æ÷Æ®]ÀÀ´äÀÚ 94.3% µµÀÔ Âù¼º¡¦Àü¹®Àû »ó´ã Àý½Ç ÀÌÁÖÇÏ 2021-09-23 314
124 [´ëÇѾà»çÀú³Î] ¾à ±¸ÀÔ ½Ã ¾à»ç¿Í »ó´ãÀÌ Áß¿ä 85% ÀÌÁö¿¬ 2021-08-10 599
123 [´ëÇѾà»çÀú³Î] ÀǾàǰ ¾ÈÀü»ç¿ë ±³À° 'µµ¿òµÆ´Ù' 98% ÀÌÁö¿¬ 2021-08-02 529
122 [´ëÇѾà»çÀú³Î] ¾ÆÆí ÇÔÀ¯ 'Á¤ÅëÆí' ÅëÁõ ¸¸º´ÅëÄ¡¾àó·³ »ç¿ë ÀÌÁö¿¬ 2021-08-02 574
121 [´ëÇѾà»çÀú³Î] ºÏÇÑÀÌÅ»ÁֹΠó¹æÀǾàǰ È¿°ú ½Å·Ú ´õ ³ô¾Æ ÀÌÁö¿¬ 2021-07-21 527
120 [´ëÇѾà»çÀú³Î] ºÏÇÑÀÌÅ»ÁֹΠÀǾàǰ Àνİú »ç¿ë ÇöȲÀº? ÀÌÁö¿¬ 2021-07-14 467
119 [´ëÇѾà»çÀú³Î] "ºÎÀÛ¿ë °æÇè 98% Áõ»ó ½Å°í¾ÈÇØ" ºÒ°¨Áõ ½É°¢ ÀÌÁö¿¬ 2021-07-07 541
118 [´ëÇѾà»çÀú³Î] ¾ÈÀü»óºñÀǾàǰ ±¸ÀÔ ¿äÀÏ ÁÖ¸» '50.3%' Â÷Áö ÀÌÁö¿¬ 2021-06-29 522
117 [´ëÇѾà»çÀú³Î] ±¹¹Î 90% 1³â°£ ÆíÀÇÁ¡ »óºñ¾à ÃÖ´ë 5ȸ ±¸ÀÔ ÀÌÁö¿¬ 2021-06-22 562
116 [´ëÇѾà»çÀú³Î] ÆíÀÇÁ¡ ºøÀå Ç®¸®ÀÚ ½ñ¾ÆÁø °¨±â¾à¡¤ÁøÅëÁ¦ ÀÌÁö¿¬ 2021-06-16 505
115 [´ëÇѾà»çÀú³Î] Áö¿ª¾à±¹ '»ý¸íÁöÅ´ÀÌ' ¿ªÇÒ ¼öÇà °ü½É ³ôÇû´Ù ÀÌÁö¿¬ 2021-06-09 512

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»